Xeris Biopharma (NASDAQ:XERS) Insider Beth Hecht Sells 16,666 Shares of Stock

Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) insider Beth Hecht sold 16,666 shares of the stock in a transaction dated Tuesday, September 1st. The stock was sold at an average price of $8.49, for a total transaction of $141,494.34. Following the transaction, the insider directly owned 1,127,796 shares of the company’s stock, valued at approximately $9,574,988.04. This trade represents a 1.46% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Beth Hecht also recently made the following trade(s):

• On Monday, August 3rd, Beth Hecht sold 16,666 shares of Xeris Biopharma stock. The stock was sold at an average price of $8.01, for a total transaction of $133,494.66.
• On Wednesday, July 1st, Beth Hecht sold 16,666 shares of Xeris Biopharma stock. The shares were sold at an average price of $8.03, for a total transaction of $133,827.98.

Xeris Biopharma Price Performance

XERS stock opened at $8.43 on Wednesday. The business’s fifty day moving average price is $8.34 and its 200 day moving average price is $6.95. Xeris Biopharma Holdings, Inc. has a 12-month low of $5.25 and a 12-month high of $10.08. The company has a current ratio of 1.45, a quick ratio of 1.02 and a debt-to-equity ratio of 17.00. The company has a market capitalization of $1.54 billion, a PE ratio of -76.64 and a beta of 0.66.

Xeris Biopharma (NASDAQ:XERS) last released its earnings results on Thursday, August 6th. The company reported ($0.18) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.01 by ($0.19). The business had revenue of $92.10 million for the quarter, compared to analyst estimates of $90.12 million. Xeris Biopharma had a positive return on equity of 338.21% and a negative net margin of 5.12%. On average, sell-side analysts anticipate that Xeris Biopharma Holdings, Inc. will post 0.07 EPS for the current year.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in the business. BlackRock Inc. purchased a new position in Xeris Biopharma during the second quarter worth about $115,042,000. Vanguard Group Inc. grew its holdings in shares of Xeris Biopharma by 13.8% during the 4th quarter. Vanguard Group Inc. now owns 11,186,677 shares of the company’s stock worth $87,815,000 after purchasing an additional 1,358,760 shares during the period. Geode Capital Management LLC increased its position in Xeris Biopharma by 3.3% during the 4th quarter. Geode Capital Management LLC now owns 4,275,989 shares of the company’s stock worth $33,571,000 after purchasing an additional 135,815 shares in the last quarter. State Street Corp increased its position in Xeris Biopharma by 10.1% during the 4th quarter. State Street Corp now owns 4,116,924 shares of the company’s stock worth $32,318,000 after purchasing an additional 378,595 shares in the last quarter. Finally, Qube Research & Technologies Ltd raised its holdings in Xeris Biopharma by 6.0% in the third quarter. Qube Research & Technologies Ltd now owns 3,274,834 shares of the company’s stock valued at $26,657,000 after buying an additional 185,063 shares during the period. Hedge funds and other institutional investors own 42.75% of the company’s stock.

Analyst Upgrades and Downgrades

A number of analysts have recently commented on XERS shares. Barclays lifted their target price on Xeris Biopharma from $9.00 to $12.00 and gave the stock an “overweight” rating in a research report on Thursday, August 20th. Wall Street Zen lowered shares of Xeris Biopharma from a “strong-buy” rating to a “buy” rating in a research report on Saturday, August 8th. Finally, Weiss Ratings lowered Xeris Biopharma from a “hold (c-)” rating to a “sell (d-)” rating in a research note on Tuesday, August 11th. Three equities research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, Xeris Biopharma presently has a consensus rating of “Hold” and an average target price of $12.00.

Xeris Biopharma Company Profile

Xeris Biopharma is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies for endocrine and orphan diseases. The company’s proprietary formulation platform is designed to enable liquid stability of drugs that traditionally require reconstitution before injection. By eliminating the need for on-site mixing and simplifying administration, Xeris aims to improve patient safety, adherence, and convenience in high-need therapeutic areas.

The company’s flagship product, Gvoke, is a ready-to-use liquid glucagon autoinjector and prefilled syringe that has been approved by the U.S.